Role of MTA2 in human cancer

Cancer and Metastasis Reviews

Volumn 33, Issue 4, 2014, Pages 921-928

  Covington, Kyle R ^a   Fuqua, Suzanne A W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Metastasis; Metastasis associated protein; MTA2; Tumor progression

Indexed keywords

HISTONE; HISTONE DEACETYLASE; METASTASIS ASSOCIATED PROTEIN 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG; MTA2 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER MORTALITY; CARCINOGENESIS; CAUSE OF DEATH; CELL INTERACTION; CELL MOTILITY; CELL SURVIVAL; DEACETYLATION; DISEASE ASSOCIATION; DNA BINDING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; PRIMARY TUMOR; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; UPREGULATION; ZINC FINGER MOTIF; BIOSYNTHESIS; BREAST TUMOR; CYTOSKELETON; FEMALE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PATHOLOGY;

BREAST NEOPLASMS; CYTOSKELETON; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; NEOPLASM METASTASIS; NEOPLASMS; REPRESSOR PROTEINS;

EID: 84919578370     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9518-0     Document Type: Article

References (55)

1. The UniProt Consortium. (2014). Activities at the Universal Protein Resource (UniProt). Nucleic Acids Research, 42(D1), D191–D198. doi:10.1093/nar/gkt1140.
2. Dephoure, N., Zhou, C., Villén, J., Beausoleil, S. A., Bakalarski, C. E., Elledge, S. J., & Gygi, S. P. (2008). A quantitative atlas of mitotic phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 105(31), 10762–10767. doi:10.1073/pnas.0805139105.
3. Mayya, V., Lundgren, D. H., Hwang, S.-I., Rezaul, K., Wu, L., Eng, J. K., & Han, D. K. (2009). Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Science Signaling, 2(84), ra46. doi:10.1126/scisignal.2000007.
4. Olsen, J. V., Vermeulen, M., Santamaria, A., Kumar, C., Miller, M. L., Jensen, L. J., & Mann, M. (2010). Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Science Signaling, 3(104), ra3. doi:10.1126/scisignal.2000475.
5. Rigbolt, K. T. G., Prokhorova, T. A., Akimov, V., Henningsen, J., Johansen, P. T., Kratchmarova, I., & Blagoev, B. (2011). System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Science Signaling, 4(164), rs3. doi:10.1126/scisignal.2001570.
6. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., & Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (New York, N.Y.), 325(5942), 834–840. doi:10.1126/science.1175371.
7. Callebaut, I., Courvalin, J. C., & Mornon, J. P. (1999). The BAH (bromo-adjacent homology) domain: a link between DNA methylation, replication and transcriptional regulation. FEBS Letters, 446(1), 189–193.
8. Boyer, L. A., Latek, R. R., & Peterson, C. L. (2004). The SANT domain: a unique histone-tail-binding module? Nature Reviews. Molecular Cell Biology, 5(2), 158–163. doi:10.1038/nrm1314.
9. Aasland, R., Stewart, A. F., & Gibson, T. (1996). The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Trends in Biochemical Sciences, 21(3), 87–88.
10. Solari, F., Bateman, A., & Ahringer, J. (1999). The Caenorhabditis elegans genes egl-27 and egr-1 are similar to MTA1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning. Development (Cambridge, England), 126(11), 2483–2494.
11. Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 408(6810), 377–381. doi:10.1038/35042612.
12. Cui, Y., Niu, A., Pestell, R., Kumar, R., Curran, E. M., Liu, Y., & Fuqua, S. A. W. (2006). Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Molecular Endocrinology, 20(9), 2020–2035. doi:10.1210/me.2005-0063.
13. Kumar, R., Wang, R.-A., & Bagheri-Yarmand, R. (2003). Emerging roles of MTA family members in human cancers. Seminar in Oncology, 30(5 Suppl 16), 30–37.
14. Bowen, N. J., Fujita, N., Kajita, M., & Wade, P. A. (2004). Mi-2/NuRD: multiple complexes for many purposes. Biochimica et Biophysica Acta, 1677(1–3), 52–57. doi:10.1016/j.bbaexp.2003.10.010.
15. Lai, A. Y., & Wade, P. A. (2011). Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nature Reviews Cancer, 11(8), 588–596. doi:10.1038/nrc3091.
16. Moon, H.-E., Cheon, H., Chun, K.-H., Lee, S. K., Kim, Y.-S., Jung, B.-K., & Lee, M.-S. (2006). Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1alpha. Oncology Reports, 16(4), 929–935.
17. Singh, R. R., & Kumar, R. (2007). MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 115–125. doi:10.1007/s10911-007-9043-7.
18. Barone, I., Brusco, L., Gu, G., Selever, J., Beyer, A., Covington, K. R., & Fuqua, S. A. W. (2011). Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Journal of the National Cancer Institute, 103(7), 538–552. doi:10.1093/jnci/djr058.
19. Covington, K. R., Brusco, L., Barone, I., Tsimelzon, A., Selever, J., Corona-Rodriguez, A., & Fuqua, S. A. W. (2013). Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment. doi:10.1007/s10549-013-2709-5.
20. Fujita, N., Jaye, D. L., Kajita, M., Geigerman, C., Moreno, C. S., & Wade, P. A. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell, 113(2), 207–219.
21. Fujita, N., Kajita, M., Taysavang, P., & Wade, P. A. (2004). Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Molecular Endocrinology, 18(12), 2937–2949. doi:10.1210/me.2004-0258.
22. Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12(5), 1479–1486. doi:10.1158/1078-0432.CCR-05-1519.
23. Fidler, I. J. (1990). Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Research, 50(19), 6130–6138.
24. Psaila, B., Kaplan, R. N., Port, E. R., & Lyden, D. (2006). Priming the “soil” for breast cancer metastasis: the pre-metastatic niche. Breast Disease, 26, 65–74.
25. Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Reviews, 25(4), 521–529. doi:10.1007/s10555-006-9036-9.
26. Fidler, I. J. (1970). Metastasis: guantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2’-deoxyuridine. Journal of the National Cancer Institute, 45(4), 773–782.
27. Fidler, I. J., & Kripke, M. L. (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197(4306), 893–895.
28. Buyse, M., Loi, S., Veer, L., van’t Viale, G., Delorenzi, M., Glas, A. M., & Consortium, T. R. A. N. S. B. I. G. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute, 98(17), 1183–1192.
29. Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., & Bertucci, F. (2011). A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment, 126(2), 407–420. doi:10.1007/s10549-010-0897-9.
30. Blick, T., Hugo, H., Widodo, E., Waltham, M., Pinto, C., Mani, S. A., & Thompson, E. W. (2010). Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. Journal of Mammary Gland Biology and Neoplasia, 15(2), 235–252. doi:10.1007/s10911-010-9175-z.
31. Alves, C. C., Carneiro, F., Hoefler, H., & Becker, K.-F. (2009). Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Frontiers in Bioscience, 14, 3035–3050.
32. Yamazaki, D., Kurisu, S., & Takenawa, T. (2005). Regulation of cancer cell motility through actin reorganization. Cancer Science, 96(7), 379–386. doi:10.1111/j.1349-7006.2005.00062.x.
33. Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., & Friedl, P. (2003). Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. The Journal of Cell Biology, 160(2), 267–277. doi:10.1083/jcb.200209006.
34. Carr, H. S., Zuo, Y., Oh, W., & Frost, J. A. (2013). Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1. Molecular and Cellular Biology, 33(14), 2773–2786. doi:10.1128/MCB.00175-13.
35. Narumiya, S., Tanji, M., & Ishizaki, T. (2009). Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Reviews, 28(1–2), 65–76. doi:10.1007/s10555-008-9170-7.
36. Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011). 2011: the immune hallmarks of cancer. Cancer Immunology, Immunotherapy: CII, 60(3), 319–326. doi:10.1007/s00262-010-0968-0.
37. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. doi:10.1016/j.cell.2011.02.013.
38. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.
39. Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., & Uhr, J. W. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152–8162. doi:10.1158/1078-0432.CCR-04-1110.
40. Schackmann, R. C. J., van Amersfoort, M., Haarhuis, J. H. I., Vlug, E. J., Halim, V. A., Roodhart, J. M. L., & Derksen, P. W. B. (2011). Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. Journal of Clinical Investigation, 121(8), 3176–3188. doi:10.1172/JCI41695.
41. Fu, J., Qin, L., He, T., Qin, J., Hong, J., Wong, J., & Xu, J. (2011). The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Research, 21(2), 275–289. doi:10.1038/cr.2010.118.
42. (EBCTCG), E. B. C. T. C. G, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., & Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784. doi:10.1016/S0140-6736(11)60993-8.
43. Goss, P. E., & Chambers, A. F. (2010). Does tumour dormancy offer a therapeutic target? Nature Reviews Cancer, 10(12), 871–877. doi:10.1038/nrc2933.
44. Heyn, C., Ronald, J. A., Ramadan, S. S., Snir, J. A., Barry, A. M., MacKenzie, L. T., & Foster, P. J. (2006). In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magnetic Resonance in Medicine, 56(5), 1001–1010. doi:10.1002/mrm.21029.
45. Riethdorf, S., & Pantel, K. (2008). Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology, 75(2), 140–148. doi:10.1159/000123852.
46. Kedrin, D., van Rheenen, J., Hernandez, L., Condeelis, J., & Segall, J. E. (2007). Cell motility and cytoskeletal regulation in invasion and metastasis. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 143–152. doi:10.1007/s10911-007-9046-4.
47. Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., & Shang, Y. (2009). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell, 138(4), 660–672. doi:10.1016/j.cell.2009.05.050.
48. Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011). Molecular signatures database (MSigDB) 3.0. Bioinformatics, 27(12), 1739–1740. doi:10.1093/bioinformatics/btr260.
49. Amano, M., Nakayama, M., & Kaibuchi, K. (2010). Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken), 67(9), 545–554. doi:10.1002/cm.20472.
50. Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., & Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117(7), 927–939.
51. Casas, E., Kim, J., Bendesky, A., Ohno-Machado, L., Wolfe, C. J., & Yang, J. (2011). Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Research, 71(1), 245–254. doi:10.1158/0008-5472.CAN-10-2330.
52. Vansteenkiste, J., Cutsem, E. V., Dumez, H., Chen, C., Ricker, J. L., Randolph, S. S., & Schöffski, P. (2008). Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investigational New Drugs, 26(5), 483–488. doi:10.1007/s10637-008-9131-6.
53. Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., & Zabel, M. D. (2010). Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One, 5(6), e11085. doi:10.1371/journal.pone.0011085.
54. Liu, G. J., Wang, Z. J., Wang, Y. F., Xu, L. L., Wang, X. L., Liu, Y., & Zeng, Y. J. (2012). Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. European Journal of Clinical Pharmacology, 68(2), 131–139. doi:10.1007/s00228-011-1100-x.
55. Ying, H., Biroc, S. L., Li, W.-W., Alicke, B., Xuan, J.-A., Pagila, R., & Dinter, H. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Molecular Cancer Therapeutics, 5(9), 2158–2164. doi:10.1158/1535-7163.MCT-05-0440.